Strategies for Protein Drug Encapsulation in Biodegradable Polymer : Size Control and Prevention of Protein Denaturation
G. Ma,Y. Wei,Y. Wang
2013-01-01
Abstract:SUMMARY The size control and prevention of protein denaturation in encapsulation of protein drugs by using biodegradable polymer PLA are two big challenges. We developed direct membrane emulsification and rapid membrane emulsification techniques instead of conventional mechanical dispersion methods to obtain uniform biodegradable microcapsules, the diameter can be controlled between 0.1 to 100 m by combining these two techniques. We employed amphiphilic polylactide-poly(ethylene glycol) (PELA) instead of polylactide (PLA) or poly(lactide-glycoside) (PLGA) to avoid denaturation of protein during encapsulation and release. It was found that PELA not only avoided the contact of proteins with hydrophobic PLA, but also retarded the pH decrease in microcapsule during PLA degradation. Recombinant growth hormone (rhGH)-loaded PELA microcapsule as a longeffective formulation with high encapsulation efficiency and high bioactivity was successfully developed. INTRODUCTION Protein drugs have been growing to an important class of therapeutic drugs, because of their low side effect, specific targeting site, and so forth. However, protein drugs showed short plasma half-life time due to their easy degradation in blood circulation, frequent injection is needed, leading to poor compliance with patients. Biodegradable PLA or PLGA microcapsules have been used to encapsulate protein drugs to solve the above problems. However, there are still several big challenges. For example, the size distribution are broad by conventional preparation technique such like mechanical stirring method, as a result, the repeatability of product is poor. Another big challenge is the denaturation of proteins during microcapsule preparation and protein release, because the rigorous mechanical shear force, interactions between protein and oil-water interface or hydrophobic PLA wall will cause the denaturation of proteins. In this study, the strategies for control of microcapsule size and prevention of protein denaturation by using polylactide-poly(ethylene glycol) (PELA) will be reported. EXPERIMENTAL METHODS Direct membrane emulsification: the primary emulsion (W1/O), where protein drug was dissolved in W1 and O was composed of polymer/solvent, was pressed through the uniform pores of the membrane into the outer water phase containing stabilizer (W2), uniform droplet (W1/O/W2) can be obtained by utilizing the high interfacial tension between dispersed phase and membrane, then the droplet can be solidified to microcapsule by evaporating the solvent in O. Rapid membrane emulsification: the coarse emulsion of W1/O/W2 with large droplet was prepared, then it was pressed quickly through the membrane under a high pressure, the large droplet can be broken into uniform smaller ones by the membrane pore under an optimized pressure. Finally, the uniform smaller microcapsules can be obtained after solidification. RESULTS AND DISCUSSION We have obtained uniform PLA, PLGA, and PELA microcapsules from W/O/W systems by optimizing various process parameters. Especially for PELA system, interfacial tension between dispersed phase and membrane, transmembrane pressure, and so forth were carefully adjusted, because PELA possess higher hydrophilicity, some of SEM photos are shown in Fig.1. The size distribution (CV value) can be controlled around 15%. Fig. 1 SEM photos of PLA (left,) and PELA (right) microcapsules prepared by direct membrane emulsification and rapid membrane emulsification techniques respectively To overcome the denaturation of protein drugs caused by contact of protein with W-O interface or hydrophobic PLA wall, PELA was designed to encapsulate rhGH, where PEG localized in W-O interface, and avoid the contact of rhGH with oil phase and hydrophobic PLA. As shown in Fig.2, the bioactivity of rhGH during 45 day’s release can be maintained above 90%, while it decreased apparently in PLA and PLGA systems. As a result, the plasma rhGH concentration can be maintained at higher value (Fig.3), and the weight gains in hypophysectomized rats increased more quickly during two months (Fig.4). Fig. 2 rhGH bioactivity released from PELA, PLA and PLGA microcapsules. The mechanism of higher rhGH bioactivity during release was studied further systematically, it was found pH value in PLA microcapsule decreased quickly due to the degradation of PLA, while PELA can retard pH decrease. As a result, the rhGH bioactivity can be maintained, and no apparent inflammatory response was observed in PELA microcapsule, compared with PLA and PLGA systems. Fig.3 The plasma rhGH concentrations in rats treated with rhGH solution and different rhGHloaded microcapsules for 2 months. Data are means ± SD for six rats per group. Fig.4 Weight gains in hypophysectomized rats treated with rhGH solution and different rhGHloaded microcapsules during 2 months. Data are means ± SD for six rats per group. CONCLUSION By combining membrane emulsification technique and material design, uniform PELA microcapsules with high rhGH bioactivity was developed as a long-effective formulation based on comparison with PLA and PLGA systems. The in vitro and in vivo studies proved our strategies were successful. REFERENCES 1. Y Wei, Y Wang, A Kang, W Wang, Sa V Ho, J Gao, G Ma, and Z Su, Molecular Pharmaceutics. 2012, 9, 2039.† 2. Y Wei, Y Wang, W Wang, Sa V Ho, W Wei, G Ma, J Mater Chem, 2011, 21, 12691. ACKNOWLEDGMENTS We would like to thank the financial support from NSFC (No.20820102036, 20706053).